AGILENT TECHNOLOGIES BELGIUM NV

Their core work

Agilent Technologies is the Belgian subsidiary of the global analytical instruments and life sciences company. In H2020 projects, they contribute analytical measurement technologies and laboratory instrumentation expertise to biomedical research consortia. Their participation spans genetics, ageing biology, and cancer research — areas where precision analytical tools are essential for translating laboratory findings into clinical understanding. They serve as a technology provider enabling other partners' research through instrumentation and measurement capabilities.

What they specialise in

How they've shifted over time

With only three projects concentrated between 2015 and 2017 start dates, there is insufficient data to identify a meaningful evolution in focus. All projects fall within the life sciences and health domain. No keyword data is available for either early or recent periods, making trend analysis unreliable.

Their latest project (GLIOTRAIN, 2017) targets glioblastoma translational research, suggesting growing interest in oncology applications for their analytical platforms.

How they like to work

Agilent participates exclusively as a partner, never as coordinator — consistent with their role as an industry technology provider embedded in academic-led consortia. Despite only three projects, they have worked with 47 unique partners across 19 countries, indicating they join large, well-funded consortia rather than small targeted collaborations. This pattern suggests they are sought after for their instrumentation capabilities rather than actively building their own research agenda.

Despite limited H2020 participation (3 projects), Agilent has connected with 47 partners across 19 countries, reflecting the large consortia typical of health research. Their network is broad but shallow — many one-time connections rather than repeated partnerships.

What sets them apart

As a multinational analytical instruments company, Agilent brings industrial-grade measurement and laboratory technology that most academic partners cannot replicate internally. Their value in consortia lies in providing validated, commercially available analytical platforms — bridging the gap between research-grade and industry-standard instrumentation. For consortium builders, Agilent offers credibility with reviewers and access to proprietary analytical workflows.

Highlights from their portfolio

• Ageing with elegans
  Largest EC contribution (EUR 188,438) and longest duration (2015-2020), focused on validating C. elegans as a healthspan model — a well-defined biological application for analytical tools.
• GLIOTRAIN
  MSCA-ITN training network on glioblastoma, indicating Agilent hosted early-stage researchers and provided industry training placements in analytical sciences.